Table 2.

Incidence rates and hazard ratios of less severe cardiovascular risk comparing concomitant use of antipsychotics and stimulants with only stimulant use^a.

Status of concomitant use	Person-months	Cases	Incidence rate (per 10,000 person months)	Adjusted hazard ratio	95% CI
No concomitant useb	1,757,687	1,007	5.73	1.00	ref
Past concomitant useb	27,917	23	8.24	1.37c	(0.89, 2.12)
Current concomitant useb	24,257	34	14.02	2.59c	(1.72, 3.90)
				1.89d	(1.10, 3.24)
Current concomitant use by AAP dosee
Average daily dose of AAP
<1 mg/day	12,353	14	11.33	2.82c	(1.72, 4.61)
1–2 mg/day	6,087	9	14.79	2.22c	(1.16, 4.25)
>2 mg/day	5,817	11	18.91	2.65c	(1.50, 4.71)
Current concomitant use by duration of usef
Cumulative days of concomitant use
<3 months	8,418	13	15.44	3.45c	(2.17, 5.47)
3–6 months	4,355	5	11.48	2.60c	(1.29, 5.25)
>6 months	11,484	16	13.93	2.61c	(1.59, 4.30)

^aData source: IQVIA PharMetrics® Plus, January 2006–December 2015.

^bThe model was adjusted for AAP daily dose, duration of AAP use, and DRS.

^cCompared with no concomitant use.

^dCompared with past concomitant use.

^eThe model was adjusted for exposure status (no, past, or current concomitant use), duration of AAP use, and DRS.

^fThe model was adjusted for exposure status (concomitant use or not), average daily dose of AAP, and DRS.